FNDX vs IBB
Schwab Fundamental US Large Company Index ETF vs iShares Biotechnology ETF
- • FNDX has the lower expense ratio at 0.25% vs 0.44% for IBB.
- • FNDX pays a higher dividend yield (1.48%).
Side-by-side metrics
| Metric | FNDX | IBB |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.25% | 0.44% |
Dividend yield Trailing 12-month yield. | 1.48% | 0.22% |
AUM Assets under management — bigger funds are typically more liquid. | $25.94B | $9.09B |
YTD return | 15.34% | 16.44% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.82 | 0.69 |
P/E ratio | 20.78 | 24.89 |
Last price | $31.31 | $197.34 |
Inception | — | — |
Issuer | Schwab | iShares |
FNDX top holdings
| AAPL | Apple Inc | 4.11% |
| INTC | Intel Corp | 2.16% |
| MSFT | Microsoft Corp | 2.12% |
| XOM | Exxon Mobil Corp | 2.12% |
| GOOGL | Alphabet Inc Class A | 1.92% |
| AMZN | Amazon.com Inc | 1.72% |
| BRK-B | Berkshire Hathaway Inc Class B | 1.64% |
| UNH | UnitedHealth Group Inc | 1.61% |
| JPM | JPMorgan Chase & Co | 1.56% |
| GOOG | Alphabet Inc Class C | 1.53% |
IBB top holdings
| VRTX | Vertex Pharmaceuticals Inc | 8.07% |
| AMGN | Amgen Inc | 7.82% |
| GILD | Gilead Sciences Inc | 6.83% |
| REGN | Regeneron Pharmaceuticals Inc | 4.90% |
| ARGX | argenx SE ADR | 3.75% |
| ALNY | Alnylam Pharmaceuticals Inc | 3.12% |
| NTRA | Natera Inc | 2.89% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.78% |
| BIIB | Biogen Inc | 2.46% |
| ILMN | Illumina Inc | 2.07% |
About FNDX
FNDX (Schwab Fundamental US Large Company Index ETF) is US large caps weighted by fundamental factors. Managed by Schwab, the fund carries $25.9B in assets under management, an expense ratio of 0.25%, a dividend yield of 1.48%. Its largest holding is Apple Inc (AAPL), which represents 4.1% of the portfolio. Real Estate is the fund's largest sector exposure at 1.9%.
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $9.1B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.22%. Its largest holding is Vertex Pharmaceuticals Inc (VRTX), which represents 8.1% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.